Clinical Trial

Safety, Tolerability, and Effectiveness of Duodenal Mucosal RF Vapor Ablation for Insulin Elimination in Type-2 Diabetes

Study acronym: STEAM-IE
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine whether RFVA of the duodenal mucosa with or without the combination of Semaglutide is a safe and effective treatment to remove the need for insulin therapy among patients with T2D who are on stable doses of insulin.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-10-22; most recent amendment 2025-11-06.
Status change: Recruiting → Active, Not Recruiting 2025-11-06
Trial Details
NCT Number NCT06655740
Lead Sponsor Aqua Medical, Inc.
Conditions Diabetes Mellitus, Type 2
Enrollment 16 participants
Start Date 2024-10-01
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-11-10